Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/2012
08/16/2012US20120207772 Anti-muc1 alpha/beta antibodies
08/16/2012US20120207771 Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
08/16/2012US20120207770 Antiproliferative agent
08/16/2012US20120207769 Inhibitors of IAP
08/16/2012US20120207767 Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors
08/16/2012US20120207765 Chemokine receptor antagonists and use thereof
08/16/2012US20120207764 Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies
08/16/2012US20120207763 Pyrrolopyrimidine compounds and their uses
08/16/2012US20120207759 Compositions and methods for modulating lymphocyte activity
08/16/2012US20120207758 CD22 Exon 12 Deletion Mutants
08/16/2012US20120207756 Modified Antibody Compositions, Methods of Making and Using Thereof
08/16/2012US20120207755 Cancer
08/16/2012US20120207753 Methods of using cd44 fusion proteins to treat cancer
08/16/2012US20120207752 Methods for modulating il-33 activity
08/16/2012US20120207751 Imidazoquinolines as lipid kinase inhibitors
08/16/2012US20120207748 T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
08/16/2012US20120207743 Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
08/16/2012US20120207742 Treatments Using PSMA Ligand Endopeptidases
08/16/2012US20120207734 Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases
08/16/2012US20120207733 Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
08/16/2012US20120207729 Substituted benzoazole pde4 inhibitors for treating pulmonary and cardiovascular disorders
08/16/2012US20120207713 Probiotic bifidobacterium strains
08/16/2012US20120207711 Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
08/16/2012US20120207708 Biomarkers for cancer-related fatigue and use thereof
08/16/2012US20120207704 Inhibiting Aberrant Blood Vessel Formation Using Growth Factor Retargeted Endopeptidases
08/16/2012US20120207681 Chemical compositions to detect and treat amyloid in a patients brain and retina
08/16/2012CA2841404A1 Treatment of angiogenesis disorders
08/16/2012CA2827017A1 B-type plexin antagonists and uses thereof
08/16/2012CA2826751A1 Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
08/16/2012CA2826622A1 Aminostatin derivatives for the treatment of arthrosis
08/16/2012CA2826387A1 Method of inhibiting hamartoma tumor cells
08/16/2012CA2824252A1 Improved immunotherapy
08/15/2012EP2487242A1 B-type plexin antagonists and uses thereof
08/15/2012EP2487189A1 Monoclonal antibodies for treatment of cancer
08/15/2012EP2487186A1 Immunoregulatory structures from normally occuring proteins
08/15/2012EP2487185A1 Hexapeptide with improved activity in the repair of cellular DNA of dermal cells
08/15/2012EP2487171A1 Dihydrobenzopyran, thiochroman, tetrahydroquinoleine and tetrahydronaphthalene derivatives and their use in anti-cancer therapy
08/15/2012EP2486929A1 Therapeutic agent for tumor
08/15/2012EP2486923A1 Histone deacetylase (HDAC) inhibiting compounds and method of making same
08/15/2012EP2486134A1 Use of toll-like receptor and agonist for treating cancer
08/15/2012EP2486061A1 Compositions and methods for the transport of therapeutic agents
08/15/2012EP2486060A1 Siglec 15 antibodies in treating bone loss-related disease
08/15/2012EP2486057A1 Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer
08/15/2012EP2486055A2 Human domain antibodies against components of the human insulin-like growth factor (igf) system
08/15/2012EP2486041A1 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
08/15/2012EP2486039A1 Purine derivatives useful as hsp90 inhibitors
08/15/2012EP2486026A1 Derivatives of di(phenylpropanoid) glycerol for the treatment of cancer
08/15/2012EP2486023A1 Potent conjugates and hydrophilic linkers
08/15/2012EP2486018A1 Substituted pyrazoles as estrogen receptor ligands
08/15/2012EP2486007A1 P-glycoprotein-specific non-competitive peptide and peptidomimetic modulators
08/15/2012EP2485804A1 Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
08/15/2012EP2485768A1 Methods and compositions related to clot-binding lipid compounds
08/15/2012EP2485760A1 Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
08/15/2012EP2485746A2 Cytoprotective or therapeutic plant composition
08/15/2012EP2485731A1 Heterocyclic compounds useful as pdk1 inhibitors
08/15/2012EP2485594A1 Combination
08/15/2012EP2485593A1 Combination
08/15/2012EP2485589A1 Heteroaryl btk inhibitors
08/15/2012EP2358710B1 Akt and p70 s6 kinase inhibitors
08/15/2012EP2271643B1 Oxadiazoles as s1p1 receptor agonists
08/15/2012EP2205268B1 Interferon alpha sequential regimen for treating cancers
08/15/2012EP2188283B1 Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
08/15/2012EP2171448B1 Methods for inhibiting tumor growth by targeting the ssdna replication intermediate of tumor stem cells
08/15/2012EP2153843B1 Compositions and methods for the diagnosis and treatment of tumor
08/15/2012EP2146988B1 New 4,8-diphenyl-polyazanaphthalene derivatives
08/15/2012EP2076542B1 Use of monoclonal antibodies specific to the o-acetylated form of gd2 ganglioside for the treatment of certain cancers
08/15/2012EP1986632B1 Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic
08/15/2012EP1705182B1 Antitumoral and antiviral peptides
08/15/2012EP1641755B1 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentlyoxybenzyl)piperidine as glucosylceramide synthase (gcs) inhibitor
08/15/2012EP1626963B1 Substituted pyrazoline compounds, their preparation and use as medicaments
08/15/2012EP1534312B1 Staphylococcal superantigens for combination treatment of lung tumors
08/15/2012EP1461347B8 2-o-(beta-d-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it
08/15/2012EP1446479B1 Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus
08/15/2012EP1438295B1 Azole derivatives and pharmaceutical compositions containing them
08/15/2012EP1420716B1 An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
08/15/2012EP1383735B1 Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
08/15/2012EP1379242B1 Method for treatment of cancer and compositions for use therein
08/15/2012EP1294391B1 Combination of agents for inhibiting transplant rejection
08/15/2012CN1351498B Pyrrolotriazines inhibitors of kinases
08/15/2012CN102639566A Bispecific binding molecules for anti-angiogenesis therapy
08/15/2012CN102639555A Bladder cancer specific ligand peptides
08/15/2012CN102639539A Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives
08/15/2012CN102639537A Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof
08/15/2012CN102639534A Purine derivatives useful as hsp90 inhibitors
08/15/2012CN102639523A Sustituted (heteroarylmethyl) thiohydantoins as anticancer drugs
08/15/2012CN102639522A Solid forms of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and methods of making the same
08/15/2012CN102639515A Compounds as lysophosphatidic acid receptor antagonists
08/15/2012CN102639510A Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof
08/15/2012CN102639503A Pyridinyl derivatives as inhibitors of enzyme nicotinamide phosphoribosyltransferase
08/15/2012CN102639497A Compounds inhibitors of enzyme lactate dehydrogenase (LDH) and pharmaceutical compositions containing these compounds
08/15/2012CN102639496A Lysine specific demethylase-1 inhibitors and their use
08/15/2012CN102639145A A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
08/15/2012CN102639142A Inhibition of endosomal toll-like receptor activation
08/15/2012CN102639131A Sublingual dexmedetomidine compositions and methods of use thereof
08/15/2012CN102639130A Methods and compositions for treating disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine d2l receptor
08/15/2012CN102639116A New oral formulations for tetrapyrrole derivatives
08/15/2012CN102634561A Application of triptolide, triptolide derivant and triptolide analogue in preparation of antitumor drugs
08/15/2012CN102634551A Algal epiphytic fungus chlorinated depside cyclic ether compound, and preparation and application thereof
08/15/2012CN102634531A Medicine T-VISA-PEA15 capable of effectively and specifically killing breast cancer cells
08/15/2012CN102634439A Shanxi vinegar
1 ... 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 ... 2211